Barclays lowered the firm’s price target on Agilent (A) to $135 from $145 and keeps an Underweight rating on the shares following the “fine” quarter. Instruments and biopharma continued to show improvement setting up for an improvement in demand in 2025, the analyst tells investors in a research note. However, the firm says timing remains uncertain in China stimulus.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on A: